A Phase 2 interventional study of Trilaciclib and Gemcitabine in Triple-Negative Breast Neoplasms, Breast Neoplasm and Breast Cancer, sponsored by G1 Therapeutics, Inc.. Terminated at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-23.
Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing gemcitabine in Triple Negative Breast Neoplasms — 2 open to participants now, 5 under way, 2 of them phase 3. Gemcitabine · Triple Negative Breast Neoplasms.
Among the 13 studies testing gemcitabine in Triple Negative Breast Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 6th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →2 of the 13 studies testing gemcitabine in Triple Negative Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Peter MacCallum Cancer Centre, Australia · Sites in Australia
Ages 18–100
The University of The West Indies · Sites in Barbados, Ghana, Jamaica
Ages 18+ · Women only
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 5
First in 2007; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 102 across the 13 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under G1 Therapeutics, Inc., one of the names counted as Pharmacosmos A/S. Under that name alone:
G1 Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
Pharmacosmos A/S has 4 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing gemcitabine in Triple Negative Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06027268Wake Forest University Health SciencesPhase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing gemcitabine in Triple Negative Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and gemcitabine (GC therapy) for participants with metastatic triple negative breast cancer.
The study was an open-label and 102 participants were randomly assigned (1:1:1 fashion) to 1 of the 3 following treatment groups:
The study included 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit.
The posted results represent the final results of Study G1T28-04, a Phase 2 study of the safety, efficacy and pharmacokinetics of trilaciclib (G1T28) in patients with locally recurrent/metastatic triple negative breast cancer receiving gemcitabine and carboplatin chemotherapy.
The final myelopreservation efficacy results are reported from database lock 1 ([DBL1], data cut-off [DCO] date of 30 July 2018). Final anti-tumor efficacy (ORR, PFS), and final summary exposure and safety data are reported from database lock 2 ([DBL2], DCO 28 June 2019) which occurred to support filing of the trilaciclib New Drug Application (NDA). Final overall survival (OS) data are reported from the final database lock which occurred on 17 July 2020 (with a last patient last visit date of 28 February 2020).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square \[mg/m\^2\] and carboplatin area under the curve \[AUC\] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).
Drug: Gemcitabine · Drug: Carboplatin
Participants received IV infusion of trilaciclib 240 mg/m\^2 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.
Drug: Trilaciclib · Drug: Gemcitabine · Drug: Carboplatin
Participants received IV infusion of trilaciclib 240 mg/m\^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.
Drug: Trilaciclib · Drug: Gemcitabine · Drug: Carboplatin
G1T28
Also known as: G1T28, CDK 4/6 Inhibitor
Gemcitabine
Carboplatin
Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1
DSN was defined as the number of days from the date of the first absolute neutrophil count (ANC) value of less than (\<) 0.5 × 10\^9 cells/liter (L) observed between Day 1 Cycle 1 and the end of Cycle 1 to the date of the first ANC value greater than or equal to (\>=) 0.5 × 10\^9/L that met the following: (1) occurred after the ANC value of \< 0.5 × 10\^9 cells/L and (2) no other ANC values \< 0.5 × 10\^9 cells/L occurred between this day and the end of Cycle 1. Severe neutropenia (SN) was set to zero for participants who did not experience severe (Grade 4) neutropenia in Cycle 1, including those who were randomized but never treated.
Time frame: From randomization to the end of Cycle 1 (Each cycle= 21 days)
Number of Participants With Severe (Grade 4) Neutropenia (SN)
Number of participants with Grade 4 SN was a binary variable. If a participants had at least 1 ANC value \< 0.5 ×10\^9/L during the treatment period, the participants was assigned as "yes" to the occurrence of SN. Otherwise, it was "no".
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
BOR was defined as the best response across all time points (RECIST v1.1). The best overall response was determined once all the data for the participant is known. Each participant has been assigned one of the following categories (RECIST 1.1): complete response (CR): disappearance of all target lesions; partial response (PR): \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; progression disease (PD): \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study); stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD); NE: not evaluable and missing.
Time frame: From date of randomization until the occurrence of progressive disease or a censoring event, assessed up to a maximum of 875 days
Duration of Objective Response (DOR) as Per RECIST v1.1 as Determined by Investigator
DOR is the time between first response by RECIST Version 1.1 of CR or PR and the first date that progressive disease is documented by RECIST Version 1.1, or death. Participants who do not experience PD or death was censored at the last tumor assessment date. 95% Confidence Interval (CI) was calculated using the Kaplan-Meier method.
Time frame: From date of randomization until the occurrence of progressive disease or a censoring event, assessed up to a maximum of 875 days
Overall Survival (OS)
Overall survival was defined as the time (months) from date of randomization to the date of death due to any cause. Participants who do not die during the study were censored at the date last known to be alive. The OS was calculated using Kaplan-Meier method.
Time frame: From date of randomization to date of death due to any cause, assessed up to a maximum of 1120 days
Progression Free Survival (PFS) as Per RECIST v1.1 as Determined by Investigator
PFS was defined as the time (months) from date of randomization until date of documented PD or death due to any cause, whichever comes first. PD: \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study). The PFS was calculated using Kaplan-Meier method.
Time frame: From date of randomization until the occurrence of disease progression, death due to any cause or a censoring event, assessed up to a maximum of 875 days
Relative Dose Intensity of Gemcitabine and Carboplatin
Relative dose intensity was defined as 100% times the actual dose intensity divided by the planned dose intensity. The planned dose intensity was defined as the cumulative planned dose through the study divided by (number of cycles × 3 weeks). Relative dose intensity (%) was calculated as: for gemcitabine (100 \* \[Dose intensity (mg/m2/week) / (2000/3 (mg/m2/week)\]); for carboplatin (100 \* \[Dose intensity (AUC/week)/ (4/3) (AUC/week)\]) and for trilaciclib (100 \* \[Dose intensity (mg/m2/week)/ (480 /3 (mg/m2/week)\] for Group 2 and 100 \* \[Dose intensity (mg/m2/week) / (960 /3 (mg/m2/week)\] for Group 3).
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Duration of Exposure
Duration of exposure (days) = First dose date of study drug from the last cycle - first dose date of study drug + 21.
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Number of Cycles Participants Received Treatment in Each Treatment Arm
Participants were considered to have started a cycle if they have received at least 1 dose of any study drug.
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Cumulative Dose of Gemcitabine
Cumulative dose: Sum of the total doses by cycle administered to a participant in the duration of exposure, i.e. total number of cycles received (milligram per meter square \[mg/m\^2\]).
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Cumulative Dose of Carboplatin
Cumulative dose: Sum of the total doses by cycle (AUC) administered to a participant in the duration of exposure, i.e. total number of cycles received (in total prescribed AUC).
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Maximum Observed Plasma Concentration (Cmax) of Trilaciclib
The observed peak plasma concentration was determined from the plasma concentration-versus time data.
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Trilaciclib
AUC0-t was calculated with the linear/log-trapezoidal method, which uses linear interpolation between data points to calculate the AUC. The linear/log-trapezoidal method will be employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method will be used for those arising from decreasing concentrations.
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Terminal Elimination Half-Life (t1/2) of Trilaciclib
t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve, the actual body exposure to drug after administration of a dose of the drug ( in mg\*h/L).
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Maximum Observed Plasma Concentration (Cmax) of Gemcitabine
The observed peak plasma concentration was determined from the plasma concentration-versus time data.
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Gemcitabine
AUC0-t was calculated with the linear/log-trapezoidal method.
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Terminal Elimination Half-Life (t1/2) of Free Carboplatin
t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Clearance (CL) of of Free Carboplatin
Clearance after intravenous infusion administration was calculated as: CL=Dose/AUC0-inf. AUC0-inf was calculated as: AUC0-inf=AUClast+Clast/lambdaz where Clast is the last quantifiable concentration in the terminal elimination phase.
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Volume of Distribution at Steady State (Vss) of Free Carboplatin
Vss was the volume of distribution at steady state of free carboplatin was reported.
Time frame: Cycle 1 Day 1 (Group 1): Pre-dose, 0.5, 1, 2, 3.5, 5, 24 hours post-dose; Cycle 1 Day 1 (Group 2) and Cycle 1 Day 2 (Group 3): Pre-dose, 0.5, 1, 1.5, 2.5, 4, 5.5, 24 hours post-dose (Each cycle is of 21 days)
Number of Participants With Grade 3 and 4 Hematologic Toxicities
Hematologic toxicities events were defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 hematologic toxicities was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 hematologic toxicities during the treatment period, the participant was assigned as Yes to the occurrence of Grade 3 and 4 hematologic toxicities; otherwise, it was No. If a participant did not have an event, the value of 0 was assigned to that participant.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Grade 3 or 4 Thrombocytopenia
Hematologic toxicities events are defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 thrombocytopenia was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 thrombocytopenia during the treatment period, the participant was assigned as "Yes" to the occurrence of Grade 3 and 4 thrombocytopenia; otherwise, it was "No". If a participant did not have an event, the value of 0 was assigned to that participant.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Major Adverse Hematologic Event (MAHE) Rate
MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelosuppression into a single endpoint by summing of the total number of events across a set of pre-specified components.The individual components for MAHE were all-cause hospitalizations, all-cause dose reductions, febrile neutropenia, prolonged severe neutropenia (duration \> 5 days), RBC transfusion and platelet transfusion. Event rate for MAHE was calculated as the number of events/durations of treatment period divided by 7 days/1 week.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Febrile Neutropenia (FN)
The criterion for identifying FN was if the PT was "FEBRILE NEUTROPENIA" the occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Infection SAEs
Number of participants with infection SAEs during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion for identifying the proper infection SAE records was as follows: If the system organ class (SOC) from Medical Dictionary for Regulatory Activities (MedDRA) takes value "INFECTIONS AND INFESTATIONS," and the AE was a serious event.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Red Blood Cell (RBC) Transfusions On/After Week 5 (Day 35)
Each RBC transfusion with a unique start date on/after 5 weeks on study during the treatment period was defined as a separate event. Occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.
Time frame: From Day 35 through the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 508 days
Number of Participants With Platelet Transfusions
Each platelet transfusion with a unique start date during the treatment period was defined as a separate event. The occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if the total number of events \>=1 was observed and No for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Granulocyte Colony-stimulating Factor (G-CSF) Administration
The criterion for selecting proper records is as follows: If the chemical subgroup from the World Health Organization-Drug Dictionary (WHO-DD) takes value "COLONY STIMULATING FACTOR," the medication was classified as G-CSF. The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Erythropoiesis Stimulating Agent (ESA) Administration
The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion to select proper records was as follows: If the chemical subgroup from WHO-DD Version September 2017 (i.e., TEXT4 for CODE4) takes value "OTHER ANTIANEMIC PREPARATIONS", the medication was classified as ESAs.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Number of Participants With Intravenous Antibiotics Use
The criteria for identifying an IV antibiotic administration event was (1) if the Therapeutic subgroup from WHO-DD version takes value "ANTIBACTERIALS FOR SYSTEMIC USE", and (2) the route of medication was "intravenous" or the route was "other" with the detailed specification as "IVPB". The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
All-cause Dose Reductions, Event Rate (Per Cycle)
Dose reductions were not permitted for trilaciclib. Dose reductions for gemcitabine or carboplatin were collected on the dosing page. No more than 3 dose modifications for toxicity in total were allowed for any participant. All dose reductions were counted as a separate event. Discontinuations of an individual component of the chemotherapy regimen were counted as a dose reduction If the participant continued the other chemotherapy drug as a monotherapy. Event rate was calculated as the total number of cycles with an event divided by the total number of cycles.
Time frame: During the treatment period. From date of randomization, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 542 days
Dose Modifications: Number of Participants With Cycle Delays
Dose modifications was summarized for each study drug based on number of cycles received during the treatment period. If the participant was unable to start a new cycle at that next visit, then the cycle is delayed, the reason entered, and the question was asked again at the next visit until the participant either starts a new cycle or discontinues treatment.
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Dose Modifications - Number of Participants With Skipped Doses
Dose modifications was summarized for each study drug based on skipped doses not received during the treatment period. Primary reasons for skipped doses included toxicity, investigator decision and administrative reasons (e.g., holidays).
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Dose Modifications: Number of Participants With Any Dose Interruptions
Dose interruptions was defined as interruption of infusion, regardless of whether the study drug was continued after the interruption.
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Dose Modifications - Number of Participants With Dose Reductions
Dose (mg/m2) reductions were not permitted for trilaciclib. Dose reductions for carboplatin and gemcitabine were determined by comparing the planned dose on the respective drug administration pages between the current cycle and the previous cycle.
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 871 days
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An Adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. Any AE that started on or after the first dose of study drugs was included as a TEAE. A Serious AE was defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) and regardless of causality that met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. TEAEs included serious and non-serious TEAEs.
Time frame: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator, assessed up to a maximum of 1116 days
This study was conducted at 34 sites in the United States (US), Belgium, Bulgaria, Croatia, Republic of Macedonia, and Serbia from 02 February 2017 (first participant enrolled) to 28 February 2020 (last participant last visit).
| Milestone | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Started | 34 | 33 | 35 |
| Itt population | 34 | 33 | 35 |
| Safety analysis set | 30 | 33 | 35 |
| Treated | 30 | 33 | 35 |
| Completed | 0 | 0 | 0 |
| Not completed | 34 | 33 | 35 |
| Withdrew: Death | 25 | 13 | 20 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 4 | 5 |
| Withdrew: Sponsor terminated | 2 | 13 | 9 |
| Withdrew: Other | 1 | 3 | 0 |
DSN was defined as the number of days from the date of the first absolute neutrophil count (ANC) value of less than (\<) 0.5 × 10\^9 cells/liter (L) observed between Day 1 Cycle 1 and the end of Cycle 1 to the date of the first ANC value greater than or equal to (\>=) 0.5 × 10\^9/L that met the following: (1) occurred after the ANC value of \< 0.5 × 10\^9 cells/L and (2) no other ANC values \< 0.5 × 10\^9 cells/L occurred between this day and the end of Cycle 1. Severe neutropenia (SN) was set to zero for participants who did not experience severe (Grade 4) neutropenia in Cycle 1, including those who were randomized but never treated.
| days | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1 | 1 ± 2.2 | 2 ± 3.5 | 1 ± 2.6 |
Number of participants with Grade 4 SN was a binary variable. If a participants had at least 1 ANC value \< 0.5 ×10\^9/L during the treatment period, the participants was assigned as "yes" to the occurrence of SN. Otherwise, it was "no".
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Grade 4 neutropenia: Yes | 9 | 12 | 8 |
| Grade 4 neutropenia: No | 25 | 21 | 27 |
BOR was defined as the best response across all time points (RECIST v1.1). The best overall response was determined once all the data for the participant is known. Each participant has been assigned one of the following categories (RECIST 1.1): complete response (CR): disappearance of all target lesions; partial response (PR): \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; progression disease (PD): \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study); stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD); NE: not evaluable and missing.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Complete response (CR) | 0 | 0 | 0 |
| Partial response (PR) | 7 | 15 | 11 |
| Stable disease (SD) | 11 | 9 | 15 |
| Progressive disease (PD) | 6 | 5 | 3 |
| Not evaluable (NE) | 0 | 0 | 1 |
| Missing | 0 | 1 | 1 |
DOR is the time between first response by RECIST Version 1.1 of CR or PR and the first date that progressive disease is documented by RECIST Version 1.1, or death. Participants who do not experience PD or death was censored at the last tumor assessment date. 95% Confidence Interval (CI) was calculated using the Kaplan-Meier method.
| months | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Duration of Objective Response (DOR) as Per RECIST v1.1 as Determined by Investigator | 7.8 (7.5 to NA) | 11.5 (4.8 to 17.8) | 9.6 (3.1 to 12.6) |
Overall survival was defined as the time (months) from date of randomization to the date of death due to any cause. Participants who do not die during the study were censored at the date last known to be alive. The OS was calculated using Kaplan-Meier method.
| months | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Overall Survival (OS) | 12.6 (6.3 to 15.6) | NA (10.2 to NA) | 17.8 (12.9 to 32.7) |
PFS was defined as the time (months) from date of randomization until date of documented PD or death due to any cause, whichever comes first. PD: \>= 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study). The PFS was calculated using Kaplan-Meier method.
| months | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Progression Free Survival (PFS) as Per RECIST v1.1 as Determined by Investigator | 5.7 (3.3 to 9.2) | 9.4 (6.1 to 11.9) | 7.3 (6.2 to 13.9) |
Relative dose intensity was defined as 100% times the actual dose intensity divided by the planned dose intensity. The planned dose intensity was defined as the cumulative planned dose through the study divided by (number of cycles × 3 weeks). Relative dose intensity (%) was calculated as: for gemcitabine (100 \* \[Dose intensity (mg/m2/week) / (2000/3 (mg/m2/week)\]); for carboplatin (100 \* \[Dose intensity (AUC/week)/ (4/3) (AUC/week)\]) and for trilaciclib (100 \* \[Dose intensity (mg/m2/week)/ (480 /3 (mg/m2/week)\] for Group 2 and 100 \* \[Dose intensity (mg/m2/week) / (960 /3 (mg/m2/week)\] for Group 3).
| percentage of dose | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Carboplatin | 77.5 ± 19.20 | 79.1 ± 15.88 | 81.7 ± 16.09 |
| Gemcitabine | 79.1 ± 18.29 | 80.8 ± 12.51 | 81.0 ± 14.49 |
Duration of exposure (days) = First dose date of study drug from the last cycle - first dose date of study drug + 21.
| days | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Duration of Exposure | 101 (21 to 469) | 161 (42 to 637) | 168 (21 to 436) |
Participants were considered to have started a cycle if they have received at least 1 dose of any study drug.
| number of cycles | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Number of Cycles Participants Received Treatment in Each Treatment Arm | 6 ± 5.0 | 9 ± 6.6 | 8 ± 4.8 |
Cumulative dose: Sum of the total doses by cycle administered to a participant in the duration of exposure, i.e. total number of cycles received (milligram per meter square \[mg/m\^2\]).
| mg/m^2 | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Cumulative Dose of Gemcitabine | 10694.3 ± 9029.11 | 14680.9 ± 11557.90 | 13277.2 ± 8722.51 |
Cumulative dose: Sum of the total doses by cycle (AUC) administered to a participant in the duration of exposure, i.e. total number of cycles received (in total prescribed AUC).
| AUC (mg/mL/min) | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Cumulative Dose of Carboplatin | 20.3 ± 16.47 | 27.8 ± 21.21 | 26.0 ± 16.33 |
The observed peak plasma concentration was determined from the plasma concentration-versus time data.
| ng/mL | Group 1: Gemcitabine/Carboplatin (Day 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Trilaciclib | — | 2280 ± 1790 | 1630 ± 423 |
AUC0-t was calculated with the linear/log-trapezoidal method, which uses linear interpolation between data points to calculate the AUC. The linear/log-trapezoidal method will be employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method will be used for those arising from decreasing concentrations.
| hour* nanogram per milliliter (h*ng/mL) | Group 1: Gemcitabine/Carboplatin (Day 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Trilaciclib | — | 3610 ± 1870 | 3800 ± 910 |
t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve, the actual body exposure to drug after administration of a dose of the drug ( in mg\*h/L).
| hours | Group 1: Gemcitabine/Carboplatin (Day 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Terminal Elimination Half-Life (t1/2) of Trilaciclib | — | 5.27 (3.98 to 6.64) | 5.31 (4.36 to 6.29) |
The observed peak plasma concentration was determined from the plasma concentration-versus time data.
| microgram per milliliter (mcg/mL) | Group 1: Gemcitabine/Carboplatin (Day 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Gemcitabine | NA ± NA | 18.0 ± 4.04 | 23.8 ± 25.9 |
AUC0-t was calculated with the linear/log-trapezoidal method.
| hour*microgram per milliliter (h*mcg/mL) | Group 1: Gemcitabine/Carboplatin (Day 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to t Hours (AUC0-t) of Gemcitabine | NA | 20.4 ± 11.6 | 15.4 ± 7.11 |
t1/2 was calculated as 0.693 divided by lambda z. lambda z (terminal phase rate constant) was determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.
| hours | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Terminal Elimination Half-Life (t1/2) of Free Carboplatin | 5.23 | 2.49 (1.32 to 2.93) | 1.79 (1.35 to 4.86) |
Clearance after intravenous infusion administration was calculated as: CL=Dose/AUC0-inf. AUC0-inf was calculated as: AUC0-inf=AUClast+Clast/lambdaz where Clast is the last quantifiable concentration in the terminal elimination phase.
| Liter/hour (L/h) | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Clearance (CL) of of Free Carboplatin | 6.65 | 14.0 ± 2.80 | 13.7 ± 4.48 |
Vss was the volume of distribution at steady state of free carboplatin was reported.
| Liter | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Volume of Distribution at Steady State (Vss) of Free Carboplatin | 44.4 | 35.0 ± 12.0 | 34.0 ± 8.99 |
Hematologic toxicities events were defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 hematologic toxicities was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 hematologic toxicities during the treatment period, the participant was assigned as Yes to the occurrence of Grade 3 and 4 hematologic toxicities; otherwise, it was No. If a participant did not have an event, the value of 0 was assigned to that participant.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with Grade 3 and 4 hematologic toxicities: Yes | 25 | 30 | 27 |
| Participants with Grade 3 and 4 hematologic toxicities: No | 9 | 3 | 8 |
Hematologic toxicities events are defined as any cycle where any hematologic lab value occurs that meets the CTCAE toxicity grade criteria for \>= Grade 3 and the value is treatment emergent. The occurrence of Grade 3 and 4 thrombocytopenia was a binary endpoint. If a participant had at least 1 cycle with at least one Grade 3 or 4 thrombocytopenia during the treatment period, the participant was assigned as "Yes" to the occurrence of Grade 3 and 4 thrombocytopenia; otherwise, it was "No". If a participant did not have an event, the value of 0 was assigned to that participant.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Number of Participants With Grade 3 or 4 Thrombocytopenia | 21 | 12 | 19 |
MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelosuppression into a single endpoint by summing of the total number of events across a set of pre-specified components.The individual components for MAHE were all-cause hospitalizations, all-cause dose reductions, febrile neutropenia, prolonged severe neutropenia (duration \> 5 days), RBC transfusion and platelet transfusion. Event rate for MAHE was calculated as the number of events/durations of treatment period divided by 7 days/1 week.
| event rate per week | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Major Adverse Hematologic Event (MAHE) Rate | 0.153 | 0.108 | 0.080 |
The criterion for identifying FN was if the PT was "FEBRILE NEUTROPENIA" the occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Number of Participants With Febrile Neutropenia (FN) | 1 | 1 | 0 |
Number of participants with infection SAEs during the treatment period was defined as a binary variable (Yes or No); Yes if total number of events \>=1 was observed, No for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion for identifying the proper infection SAE records was as follows: If the system organ class (SOC) from Medical Dictionary for Regulatory Activities (MedDRA) takes value "INFECTIONS AND INFESTATIONS," and the AE was a serious event.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with Infection SAEs: Yes | 2 | 0 | 0 |
| Participants with Infection SAEs: No | 32 | 33 | 35 |
Each RBC transfusion with a unique start date on/after 5 weeks on study during the treatment period was defined as a separate event. Occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with RBC transfusions on/after Week 5: Yes | 12 | 11 | 8 |
| Participants with RBC transfusions on/after Week 5: No | 22 | 22 | 27 |
Each platelet transfusion with a unique start date during the treatment period was defined as a separate event. The occurrence during the treatment period was defined as a binary variable (Yes or No); Yes if the total number of events \>=1 was observed and No for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with platelet transfusion: Yes | 4 | 3 | 6 |
| Participants with platelet transfusion: No | 30 | 30 | 29 |
The criterion for selecting proper records is as follows: If the chemical subgroup from the World Health Organization-Drug Dictionary (WHO-DD) takes value "COLONY STIMULATING FACTOR," the medication was classified as G-CSF. The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if the total number of events \>=1 was observed and "No" for other scenarios. If a participant did not have an event, the value of 0 will be assigned to that participant.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with G-CSF Administration: Yes | 16 | 21 | 14 |
| Participants with G-CSF Administration: No | 18 | 12 | 21 |
The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant. The criterion to select proper records was as follows: If the chemical subgroup from WHO-DD Version September 2017 (i.e., TEXT4 for CODE4) takes value "OTHER ANTIANEMIC PREPARATIONS", the medication was classified as ESAs.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with ESA Administration: Yes | 4 | 2 | 3 |
| Participants with ESA Administration: No | 30 | 31 | 32 |
The criteria for identifying an IV antibiotic administration event was (1) if the Therapeutic subgroup from WHO-DD version takes value "ANTIBACTERIALS FOR SYSTEMIC USE", and (2) the route of medication was "intravenous" or the route was "other" with the detailed specification as "IVPB". The occurrence during the treatment period was defined as a binary variable (Yes or No); "Yes" if total number of events \>=1 was observed, "No" for other scenarios. If a participant did not have an event, the value of 0 was assigned to that participant.
| Participants | Group 1: Gemcitabine/Carboplatin (Day 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with Intravenous Antibiotics Use: Yes | 6 | 5 | 0 |
| Participants with Intravenous Antibiotics Use: No | 28 | 28 | 35 |
Dose reductions were not permitted for trilaciclib. Dose reductions for gemcitabine or carboplatin were collected on the dosing page. No more than 3 dose modifications for toxicity in total were allowed for any participant. All dose reductions were counted as a separate event. Discontinuations of an individual component of the chemotherapy regimen were counted as a dose reduction If the participant continued the other chemotherapy drug as a monotherapy. Event rate was calculated as the total number of cycles with an event divided by the total number of cycles.
| event rate per cycle | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| All-cause Dose Reductions, Event Rate (Per Cycle) | 0.141 | 0.118 | 0.133 |
Dose modifications was summarized for each study drug based on number of cycles received during the treatment period. If the participant was unable to start a new cycle at that next visit, then the cycle is delayed, the reason entered, and the question was asked again at the next visit until the participant either starts a new cycle or discontinues treatment.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Dose Modifications: Number of Participants With Cycle Delays | 17 | 19 | 22 |
Dose modifications was summarized for each study drug based on skipped doses not received during the treatment period. Primary reasons for skipped doses included toxicity, investigator decision and administrative reasons (e.g., holidays).
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Dose Modifications - Number of Participants With Skipped Doses | 15 | 20 | 13 |
Dose interruptions was defined as interruption of infusion, regardless of whether the study drug was continued after the interruption.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Trilaciclib | NA | 3 | 5 |
| Carboplatin | 1 | 1 | 0 |
| Gemcitabine | 2 | 4 | 0 |
Dose (mg/m2) reductions were not permitted for trilaciclib. Dose reductions for carboplatin and gemcitabine were determined by comparing the planned dose on the respective drug administration pages between the current cycle and the previous cycle.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Carboplatin | 10 | 13 | 15 |
| Gemcitabine | 13 | 20 | 17 |
An Adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. Any AE that started on or after the first dose of study drugs was included as a TEAE. A Serious AE was defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) and regardless of causality that met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. TEAEs included serious and non-serious TEAEs.
| Participants | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| Participants with any TEAEs | 30 | 33 | 34 |
| Participants with any Serious TEAEs | 10 | 11 | 4 |
Collected over From date of randomization up to 1121 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | 25/30 (83.3%) | 10/30 (33.3%) | 30/30 (100%) |
| Group 2: Trilaciclib (G1T28)+ Gemcitabine/Carboplatin (Days 1 and 8) | 13/33 (39.4%) | 11/33 (33.3%) | 33/33 (100%) |
| Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) | 20/35 (57.1%) | 4/35 (11.4%) | 34/35 (97.1%) |
| Event | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib (G1T28)+ Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| CellulitisInfections and infestations | 2/30 | 0/33 | 0/35 |
| Platelet count decreasedInvestigations | 0/30 | 2/33 | 0/35 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/30 | 2/33 | 0/35 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/30 | 2/33 | 0/35 |
| HypertensionVascular disorders | 1/30 | 0/33 | 0/35 |
| HypotensionVascular disorders | 1/30 | 0/33 | 0/35 |
| PainGeneral disorders | 1/30 | 0/33 | 0/35 |
| Acute myocardial infarctionCardiac disorders | 1/30 | 0/33 | 0/35 |
| Right ventricular failureCardiac disorders | 1/30 | 0/33 | 0/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/30 | 1/33 | 0/35 |
| Event | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib (G1T28)+ Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 22/30 | 16/33 | 15/35 |
| NauseaGastrointestinal disorders | 7/30 | 14/33 | 17/35 |
| FatigueGeneral disorders | 11/30 | 14/33 | 16/35 |
| NeutropeniaBlood and lymphatic system disorders | 13/30 | 15/33 | 12/35 |
| ThrombocytopeniaBlood and lymphatic system disorders | 13/30 | 13/33 | 11/35 |
| HeadacheNervous system disorders | 6/30 | 9/33 | 14/35 |
| Neutrophil count decreasedInvestigations | 8/30 | 12/33 | 11/35 |
| Platelet count decreasedInvestigations | 8/30 | 8/33 | 12/35 |
| VomitingGastrointestinal disorders | 8/30 | 8/33 | 11/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/30 | 9/33 | 6/35 |
The ITT analysis set included all randomized participants.
| Age, Continuous(years) | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) | Total |
|---|---|---|---|---|
| Mean | 55 ± 13.6 | 56 ± 12.1 | 58 ± 9.5 | 56 ± 11.8 |
| Sex: Female, Male(Participants) | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) | Total |
|---|---|---|---|---|
| Female | 34 | 32 | 35 | 101 |
| Male | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 2 | 9 |
| Not Hispanic or Latino | 32 | 28 | 33 | 93 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Gemcitabine/Carboplatin (Days 1 and 8) | Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) | Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 7 | 2 | 14 |
| White | 28 | 22 | 28 | 78 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Jun 2019, 28 months.
Results were first posted in Mar 2022, 2 years 8 months after primary completion. A results delay was requested in Jul 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Carboplatin
Triple Negative Breast Neoplasms →